Melanoma (Skin) Clinical Trial
— TavieSkinOfficial title:
A Prospective Non Interventional Study on Targeted Therapy for Patients With Unresectable or Metastatic BRAFV600E Mutant Melanoma
1. Background The purpose of this study is to describe the profile of patients with BRAF-mutated melanoma treated with BRAF/MEK inhibitors combination and using the Tavie Skin application. TavieSkin app, a digital solution developped by Pierre Fabre, is dedicated to all BRAF-mutant unresectable or metastatic melanoma patients who are treated with "any" targeted therapies. 2. Study objectives The primary objective of the survey is to describe the demographics and clinical characteristics of patients with unresectable or metastatic BRAF-mutated melanoma treated with targeted therapy (BRAFi/MEKi) and using the TavieSkin application The secondary objectives include: - To assess the use of TavieSkin app in patients with unresectable or metastatic BRAF-mutated melanoma treated with BRAFi/MEKi combination; - To assess the treatment adherence of patients using TavieSkin app including treatment interruption or permanent discontinuation; - To assess the health-related quality of life of patients using TavieSkin app (FACT-M); - To assess work productivity and activity impairment over the treatment duration - To assess the patient satisfaction toward the TavieSkin application; - To assess the patient satisfaction toward the treatment. 3. Research methods 3.1 Study design This prospective, longitudinal, survey will be conducted in Europe to characterize BRAF-mutant unresectable or metastatic melanoma patients using TavieSkin app designed for accompanying patients treated with targeted therapies. To date, there are three combinations of BRAFi/MEKi available in routine practice for the treatment of BRAF-mutant unresectable or metastatic melanoma. The survey does not provide or recommend any treatment or procedure; all decisions regarding treatment are made at the sole discretion of the treating physicians in accordance with their usual practices. The patients initiating any BRAFi/MEKi combination will be invited to use the TavieSkin app by their healthcare provider (HCP) (i.e. oncologist, dermatologist, nurse…). Once the patient has installed and started to use the application, an e-survey will be proposed to the patient via the app. A detailed information letter about the data collection, data privacy and analysis will be displayed to the patient via the app along with an e-consent for data collection. The patient will be able then to provide an e-signature, if he/she accepts to take part of this survey. The survey will collect anonymized data about health status, QoL data and satisfaction. These data will be collected by the patient only. The physician will not be involved in this e-survey (including e-consent), nor in data collection. Only patients having given consent (e-consent) to data collection and analysis will be included. Data will be collected at baseline and at different subsequent timepoints during the BRAFi/MEKi treatment duration only. Only data reported by the patients in the application will be collected and analyzed. The patient will discontinue the study in case of definitive withdrawal of BRAFi/MEKi treatment, or if he/she decides to withdraw the study and to stop data collection. The target countries for patient enrollment will include Germany, Belgium, Portugal, France, Spain, Italy and Sweden with the additional possibility of including patients from other EU countries. At least, 400 adult patients (≥18 years) will be enrolled. 3.2 Population (see section: Eligibility) 3.3 Study outcomes (see section: Outcome measures) 3.4 Statistical considerations Statistical analyses will be fully described in a written statistical analysis plan (SAP). The study endpoints will be analysed overall and by country. Analyses will be descriptive in nature, as no hypothesis will be tested. The treatment patterns of patients, baseline demographics and clinical characteristics, and reasons for treatment discontinuation will be described using summary statistics. Categorical variables will be summarized by frequencies and percentages. Continuous variables will be summarized by descriptive statistics (mean, and standard deviation, median, 25th and 75th percentiles, minimum and maximum). The number of missing observations for each variable will also be reported. Change in health-related quality-of-life scores (i.e. (FACT-M) will be summarised at baseline and at each timepoints. The change from baseline will be assessed using a mixed model for repeated measures (MMRM). Time to event data (i.e. time to treatment discontinuation, time QoL deterioration) will be evaluated using Kaplan-Meier survival curves. Median survival estimates will be reported along with the 25th and 75th percentiles and corresponding 95% confidence intervals (CIs). Cox regression analysis may be performed to adjust for predefined (baseline) covariates. If the sample size is adequate, subgroup analyses using variables at baseline might be conducted.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | December 2024 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Only patients starting to use the TavieSkin app will be eligible for enrollment in the survey. The patient should meet all the following inclusion criteria to be eligible for participating: - Male or female aged =18 years at diagnosis of unresectable or metastatic melanoma; - Diagnosis of histologically or cytologically confirmed BRAF-mutant melanoma that is metastatic or unresectable, documented as per routine practice - Patient having an ongoing prescription of one of the three commercially available BRAFi/MEKi combination therapy, at any line of treatment - Patient using the TavieSkin app and having signed an informed consent (e-consent via the app) for data collection , according to local regulations Exclusion Criteria: Patients will be excluded from the survey if they fulfil any of the following criteria: - Patients with other BRAFi/MEKi combination than those available on the market - Patient receiving a BRAFi/MEKi combination in the adjuvant setting - Patients under guardianship because of mental illness or any other reason - Patients treated with a treatment that is not licensed for local use (including approved BRAFi/MEKi combination associated with another product) |
Country | Name | City | State |
---|---|---|---|
Portugal | Hospital Evora | Evora |
Lead Sponsor | Collaborator |
---|---|
Pierre Fabre Medicament |
Portugal,
Arance Fernández, A. M. et al. Epidemiological study to evaluate the prevalence of BRAF V600 mutation in patients (pts) diagnosed with advanced melanoma (AM) in routine clinical practice in Spain. J. Clin. Oncol. 33, e20115-e20115 (2015). DOI:10.1200/jco.2015.33.15_suppl.e20115
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004 Feb 26;2:12. — View Citation
Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10. — View Citation
Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, Fonsatti E, Maio M, Botti G, Caracò C, Mozzillo N, Ascierto PA, Cossu A, Palmieri G. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med. 2013 Aug 29;11:202. doi: 10.1186/1479-5876-11-202. — View Citation
Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, Lundgren L, Ingvar C, Jönsson G. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol. 2013 Nov;169(5):1049-55. doi: 10.1111/bjd.12504. — View Citation
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13. — View Citation
Haase J, Farris KB, Dorsch MP. Mobile Applications to Improve Medication Adherence. Telemed J E Health. 2017 Feb;23(2):75-79. doi: 10.1089/tmj.2015.0227. Epub 2016 Jun 1. Review. — View Citation
Henshall C, Davey Z, Jacelon C, Martin C. A usability study to test the effectiveness, efficiency and simplicity of a newly developed Internet-based Exercise-focused Health App for Lung cancer survivors (iEXHALE): Protocol paper. Health Informatics J. 2020 Jun;26(2):1431-1442. doi: 10.1177/1460458219882268. Epub 2019 Oct 21. — View Citation
Hinz A, Singer S, Brähler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol. 2014 Jul;53(7):958-65. doi: 10.3109/0284186X.2013.879998. Epub 2014 Jan 23. — View Citation
Iribarren SJ, Cato K, Falzon L, Stone PW. What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions. PLoS One. 2017 Feb 2;12(2):e0170581. doi: 10.1371/journal.pone.0170581. eCollection 2017. Review. — View Citation
Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25. — View Citation
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22. — View Citation
McKay FH, Cheng C, Wright A, Shill J, Stephens H, Uccellini M. Evaluating mobile phone applications for health behaviour change: A systematic review. J Telemed Telecare. 2018 Jan;24(1):22-30. doi: 10.1177/1357633X16673538. Epub 2016 Oct 18. Review. — View Citation
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Dec 1;30(12):1884-1901. doi: 10.1093/annonc/mdz411. — View Citation
Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006 Jul 6;355(1):51-65. Review. — View Citation
Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, Marin C, Peschaud F, Chagnon S, Zimmermann U, Clerici T, Emile JF. Prognostic value of BRAF(V6°°) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol. 2012 Dec;19(13):4314-21. doi: 10.1245/s10434-012-2457-5. Epub 2012 Jul 7. — View Citation
Osborn J, Ajakaiye A, Cooksley T, Subbe CP. Do mHealth applications improve clinical outcomes of patients with cancer? A critical appraisal of the peer-reviewed literature. Support Care Cancer. 2020 Mar;28(3):1469-1479. doi: 10.1007/s00520-019-04945-4. Epub 2019 Jul 4. Review. — View Citation
Picard M, Pham Dang N, D'Incan M, Mansard S, Dechelotte P, Pereira B, Mondie JM, Barthelemy I. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. Br J Dermatol. 2014 Jul;171(1):108-14. doi: 10.1111/bjd.12939. Epub 2014 Jul 7. — View Citation
Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S. Update in genetic susceptibility in melanoma. Ann Transl Med. 2015 Sep;3(15):210. doi: 10.3978/j.issn.2305-5839.2015.08.11. Review. — View Citation
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5):353-65. — View Citation
Rutkowski P, Gos A, Jurkowska M, Switaj T, Dziewirski W, Zdzienicki M, Ptaszynski K, Michej W, Tysarowski A, Siedlecki JA. Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. Oncol Lett. 2014 Jul;8(1):47-54. Epub 2014 May 8. — View Citation
Ryu S, Youn C, Moon AR, Howland A, Armstrong CA, Song PI. Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J. 2017 Sep;53(3):173-177. doi: 10.4068/cmj.2017.53.3.173. Epub 2017 Sep 25. Review. — View Citation
Sauro, J. A practical guide to the system usability scale: background, benchmarks & best practices. Denver, CO: Measuring Usability LLC, 2011
Schoffer O, Schülein S, Arand G, Arnholdt H, Baaske D, Bargou RC, Becker N, Beckmann MW, Bodack Y, Böhme B, Bozkurt T, Breitsprecher R, Buchali A, Burger E, Burger U, Dommisch K, Elsner G, Fernschild K, Flintzer U, Funke U, Gerken M, Göbel H, Grobe N, Gumpp V, Heinzerling L, Kempfer LR, Kiani A, Klinkhammer-Schalke M, Klöcking S, Kreibich U, Knabner K, Kuhn P, Lutze S, Mäder U, Maisel T, Maschke J, Middeke M, Neubauer A, Niedostatek A, Opazo-Saez A, Peters C, Schell B, Schenkirsch G, Schmalenberg H, Schmidt P, Schneider C, Schubotz B, Seide A, Strecker P, Taubenheim S, Wackes M, Weiß S, Welke C, Werner C, Wittekind C, Wulff J, Zettl H, Klug SJ. Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011. BMC Cancer. 2016 Dec 5;16(1):936. — View Citation
Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol. 2016 May 26;8:109-22. doi: 10.2147/CLEP.S99021. eCollection 2016. Review. — View Citation
* Note: There are 25 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of age | Age will be assessed in years (date of the initiation of targeted therapy - date of birth) | Baseline | |
Primary | Description of Sex | Sex will be described in percentage of Male and Female among the participants | Baseline | |
Primary | Description of BMI | Weight (in kg) and height (in m) will be combined to report BMI in kg/m2 | Baseline | |
Primary | Description of sociodemographic status: country | The country will be described in number of participants included in each country (France, Portugal, Spain, Belgium, Germany, Italy) | Baseline | |
Primary | Description of sociodemographic status: education level | The education level will be described by the following distribution of participants: with no degree/Primary education, High school level or equivalent and with college degree (i.e. Bachelor, Master or Doctorate) | Baseline | |
Primary | Description of sociodemographic status: employment status | The employment status will be described by the following distribution of participants: employed, unemployed, retired and student | Baseline | |
Primary | Description of sociodemographic status: living place | The living place will be described by the following distribution of participants: living in urban/suburban and in rural | Baseline | |
Primary | Description of sociodemographic status: family situation | The family situation will be described by the following distribution of participants: living alone, cohabiting or living with family members and other | Baseline | |
Primary | Description of clinical characteristics of patients: time since initial diagnostic of melanoma | The time since initial diagnostic of melanoma will be assessed in number of years (date of the initiation of targeted therapy - date of initial diagnostic of melanoma) | Baseline | |
Primary | Description of clinical characteristics of patients: time since metastatic diagnosis | The time since metastatic diagnosis will be assessed in number of years (date of the initiation of targeted therapy - date of metastatic diagnosis) | Baseline | |
Primary | Description of clinical characteristics of patients: initial/primary site of tumor | The Initial/primary site of tumor will be described by the following distribution of participants: with localization in the upper extremities, head and neck, trunk, lower extremities, mucosal or uvea, unknown localization | Baseline | |
Primary | Description of clinical characteristics of patients: comorbidities | The comorbidities will be described by the following distribution of participants: with diabetes, hypertension, renal failure, cardiovascular disease, other cancer, autoimmune disease, … | Baseline | |
Primary | Description of clinical characteristics of patients: prior therapies for melanoma | The prior therapies for melanoma will be described by the following distribution of participants: treated with surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, other | Baseline | |
Secondary | Assessment of the use of TavieSkin application:number of subscribers who frequently use the application | The use of TavieSkin app will be assessed using the app usage data such as the number of subscribers who frequently use the application | Every day during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of the use of TavieSkin application: duration of usage per day | The use of TavieSkin app will be assessed using the app usage data such as the duration of usage per day (in number of minutes per day) | Every day during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of the use of TavieSkin application: rate of completed data and completed questionnaires | The use of TavieSkin app will be assessed using the app usage data such as the rate of completed data and completed questionnaires | Every day during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of the adherence to treatment | The adherence to treatment will be assessed by describing the effective taken medication. The frequency of treatment interruption and permanent discontinuation as reported by the patient will be described. | Every day during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of health-related quality of life. | The health-related quality of life of patients will be described using the Functional Assessment of Cancer Therapy - Melanoma (FACT-M) score. The score range is 0-172, higher scores mean a better quality of life. | Baseline, then every 6 weeks during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of the activity and the physical function | Activity and physical function at baseline will be assessed using the World Health Organization (WHO) score | Baseline, then every month during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of Work productivity and activity impairment | Work productivity and activity impairment (WPAI) will be assessed using the Specific Health Problem (SHP) V2.0, the WPAI:SHP questionnaire | Baseline, then every 2 months during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of the patient satisfaction toward the TavieSkin application | The patient satisfaction toward the TavieSkin application will be assessed using the System Usability Scale (SUS) score. The score range is 0-100, higher scores mean a better satisfaction. | Every 2 months during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first | |
Secondary | Assessment of the patient satisfaction toward the treatment | The patient satisfaction toward the treatment will be assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM-9) | Every 2 months during targeted therapy until targeted therapy discontinuation or study completion, an average of 1 year, whichever comes first |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |